A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients

Alon Harris, Oliver Arend, Hak Sung Chung, Larry Kagemann, Louis Cantor, Bruce Martin

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Objective: To determine whether dosages of a selective β-blocking agent (betaxolol) and a topical carbonic anhydrase inhibitor (dorzolamide), sufficient to significantly lower intraocular pressure (IOP), have similar or disparate impact on the retinal and retrobulbar circulation. Design: Counterbalanced crossover, with open-label use of medications. Participants: Nine persons with normal-tension glaucoma (NTG). Intervention: After a 3-week drug washout, NTG patients were studied after 1 month of treatment with either dorzolamide or betaxolol, with determinations of IOP and retinal and retrobulbar hemodynamics. Main Outcome Measures: At baseline and after treatment with each drug, retinal arteriovenous passage time was determined by scanning laser ophthalmoscopy after fluorescein dye injection, and flow velocities in the central retinal and ophthalmic arteries were measured with color Doppler ultrasonography imaging. Results: Betaxolol and dorzolamide each lowered IOP significantly, with these changes apparent and maximal after 2 weeks (each P < 0.05). In contrast, dorzolamide (but not betaxolol) accelerated arteriovenous passage of fluorescein dye in the inferior temporal quadrant of the retina (P < 0.05). Neither drug affected arteriovenous passage in the superotemporal retina or any aspect of central retinal or ophthalmic artery flow velocity after either 2 or 4 weeks. Conclusions: Although both dorzolamide and betaxolol are effective ocular hypotensive agents and their topical instillation leaves retrobulbar hemodynamics unaltered, dorzolamide alone accelerates inferotemporal retinal dye transit. (C) 2000 by the American Academy of Ophthalmology.

Original languageEnglish
Pages (from-to)430-434
Number of pages5
JournalOphthalmology
Volume107
Issue number3
DOIs
StatePublished - Mar 2000

Fingerprint

dorzolamide
Betaxolol
Low Tension Glaucoma
Intraocular Pressure
Ophthalmic Artery
Retinal Artery
Coloring Agents
Fluorescein
Retina
Hemodynamics
Pharmaceutical Preparations
Carbonic Anhydrase Inhibitors
Doppler Color Ultrasonography
Ophthalmoscopy
Cross-Over Studies
Lasers
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. / Harris, Alon; Arend, Oliver; Chung, Hak Sung; Kagemann, Larry; Cantor, Louis; Martin, Bruce.

In: Ophthalmology, Vol. 107, No. 3, 03.2000, p. 430-434.

Research output: Contribution to journalArticle

Harris, Alon ; Arend, Oliver ; Chung, Hak Sung ; Kagemann, Larry ; Cantor, Louis ; Martin, Bruce. / A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. In: Ophthalmology. 2000 ; Vol. 107, No. 3. pp. 430-434.
@article{1276587a883f412b9afbf61c5a51cbd3,
title = "A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients",
abstract = "Objective: To determine whether dosages of a selective β-blocking agent (betaxolol) and a topical carbonic anhydrase inhibitor (dorzolamide), sufficient to significantly lower intraocular pressure (IOP), have similar or disparate impact on the retinal and retrobulbar circulation. Design: Counterbalanced crossover, with open-label use of medications. Participants: Nine persons with normal-tension glaucoma (NTG). Intervention: After a 3-week drug washout, NTG patients were studied after 1 month of treatment with either dorzolamide or betaxolol, with determinations of IOP and retinal and retrobulbar hemodynamics. Main Outcome Measures: At baseline and after treatment with each drug, retinal arteriovenous passage time was determined by scanning laser ophthalmoscopy after fluorescein dye injection, and flow velocities in the central retinal and ophthalmic arteries were measured with color Doppler ultrasonography imaging. Results: Betaxolol and dorzolamide each lowered IOP significantly, with these changes apparent and maximal after 2 weeks (each P < 0.05). In contrast, dorzolamide (but not betaxolol) accelerated arteriovenous passage of fluorescein dye in the inferior temporal quadrant of the retina (P < 0.05). Neither drug affected arteriovenous passage in the superotemporal retina or any aspect of central retinal or ophthalmic artery flow velocity after either 2 or 4 weeks. Conclusions: Although both dorzolamide and betaxolol are effective ocular hypotensive agents and their topical instillation leaves retrobulbar hemodynamics unaltered, dorzolamide alone accelerates inferotemporal retinal dye transit. (C) 2000 by the American Academy of Ophthalmology.",
author = "Alon Harris and Oliver Arend and Chung, {Hak Sung} and Larry Kagemann and Louis Cantor and Bruce Martin",
year = "2000",
month = "3",
doi = "10.1016/S0161-6420(99)00093-7",
language = "English",
volume = "107",
pages = "430--434",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients

AU - Harris, Alon

AU - Arend, Oliver

AU - Chung, Hak Sung

AU - Kagemann, Larry

AU - Cantor, Louis

AU - Martin, Bruce

PY - 2000/3

Y1 - 2000/3

N2 - Objective: To determine whether dosages of a selective β-blocking agent (betaxolol) and a topical carbonic anhydrase inhibitor (dorzolamide), sufficient to significantly lower intraocular pressure (IOP), have similar or disparate impact on the retinal and retrobulbar circulation. Design: Counterbalanced crossover, with open-label use of medications. Participants: Nine persons with normal-tension glaucoma (NTG). Intervention: After a 3-week drug washout, NTG patients were studied after 1 month of treatment with either dorzolamide or betaxolol, with determinations of IOP and retinal and retrobulbar hemodynamics. Main Outcome Measures: At baseline and after treatment with each drug, retinal arteriovenous passage time was determined by scanning laser ophthalmoscopy after fluorescein dye injection, and flow velocities in the central retinal and ophthalmic arteries were measured with color Doppler ultrasonography imaging. Results: Betaxolol and dorzolamide each lowered IOP significantly, with these changes apparent and maximal after 2 weeks (each P < 0.05). In contrast, dorzolamide (but not betaxolol) accelerated arteriovenous passage of fluorescein dye in the inferior temporal quadrant of the retina (P < 0.05). Neither drug affected arteriovenous passage in the superotemporal retina or any aspect of central retinal or ophthalmic artery flow velocity after either 2 or 4 weeks. Conclusions: Although both dorzolamide and betaxolol are effective ocular hypotensive agents and their topical instillation leaves retrobulbar hemodynamics unaltered, dorzolamide alone accelerates inferotemporal retinal dye transit. (C) 2000 by the American Academy of Ophthalmology.

AB - Objective: To determine whether dosages of a selective β-blocking agent (betaxolol) and a topical carbonic anhydrase inhibitor (dorzolamide), sufficient to significantly lower intraocular pressure (IOP), have similar or disparate impact on the retinal and retrobulbar circulation. Design: Counterbalanced crossover, with open-label use of medications. Participants: Nine persons with normal-tension glaucoma (NTG). Intervention: After a 3-week drug washout, NTG patients were studied after 1 month of treatment with either dorzolamide or betaxolol, with determinations of IOP and retinal and retrobulbar hemodynamics. Main Outcome Measures: At baseline and after treatment with each drug, retinal arteriovenous passage time was determined by scanning laser ophthalmoscopy after fluorescein dye injection, and flow velocities in the central retinal and ophthalmic arteries were measured with color Doppler ultrasonography imaging. Results: Betaxolol and dorzolamide each lowered IOP significantly, with these changes apparent and maximal after 2 weeks (each P < 0.05). In contrast, dorzolamide (but not betaxolol) accelerated arteriovenous passage of fluorescein dye in the inferior temporal quadrant of the retina (P < 0.05). Neither drug affected arteriovenous passage in the superotemporal retina or any aspect of central retinal or ophthalmic artery flow velocity after either 2 or 4 weeks. Conclusions: Although both dorzolamide and betaxolol are effective ocular hypotensive agents and their topical instillation leaves retrobulbar hemodynamics unaltered, dorzolamide alone accelerates inferotemporal retinal dye transit. (C) 2000 by the American Academy of Ophthalmology.

UR - http://www.scopus.com/inward/record.url?scp=0034073121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034073121&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(99)00093-7

DO - 10.1016/S0161-6420(99)00093-7

M3 - Article

C2 - 10711877

AN - SCOPUS:0034073121

VL - 107

SP - 430

EP - 434

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 3

ER -